« Return to News | Drug Sponsors

ImaginAb, Lundbeck to collaborate in neurodegeneration

Wednesday, October 10, 2012 12:49 PM

ImaginAb, an Inglewood, Calif.-based clinical-stage company developing in vivo molecular imaging agents, has entered into a collaboration and commercialization agreement with Lundbeck, an international pharmaceutical company, on a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

"This collaboration represents a great opportunity for both companies to explore an increasingly important intersection between therapeutic and diagnostic medicine," said Christian Behrenbruch, CEO of ImaginAb. "Given the worrying number of recent failures of late-stage biologics programs, including for neurodegenerative applications, there is a critical need to explore new ways of integrating diagnostic and therapeutic strategies to de-risk development."

The parties will collaborate to concurrently develop biologics with improved BBB transport and imaging agents that are capable of quantitating kinetics and targeting efficacy. The agreement also includes an option for Lundbeck to commercialize the results of the collaboration for both diagnostic and therapeutic uses.

"Molecular imaging has become a prevalent aspect of developing new CNS products, both during product development and for clinical management of disease, and we are pleased to be working with ImaginAb to explore this exciting opportunity," said Jeffrey Stavenhagen, head of biologics, Lundbeck.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.